Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2009 Oct;10(14):2269-77. doi: 10.1517/14656560903120907.

Antiangiogenic drugs in ovarian cancer.

Author information

  • 1The University of Texas MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, Houston, Texas 77005, USA. mmarkman@mdanderson.org

Abstract

BACKGROUND:

There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer.

OBJECTIVE:

The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer.

RESULTS/CONCLUSION:

Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.

PMID:
19671017
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk